Seres Therapeutics has transitioned into a leaner, R&D-focused entity following the divestiture of its primary commercial asset, yet the firm faces significant sustainability challenges.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$1.63-63.0% vs -$1.00 | $593,000-90.7% vs $6M |
Q3 2026 Aug 5, 2026 | $0.47+121.6% vs -$2.18 | $736,000+311.2% vs $179,000 |
Q2 2026 May 5, 2026 | -$2.08-10.6% vs -$1.88 | $358,000+0.0% vs $358,000 |
Q2 2026 Mar 12, 2026 | -$1.78+25.5% vs -$2.39 | $438,000-91.7% vs $5M |
Seres Therapeutics (MCRB) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.34. This compares to earnings of $0.94 per share a year ago.
Prevention approach aims to keep patients on immune checkpoint inhibitor (ICI) therapy and avoid immunosuppressive irEC treatments, representing an additional broad therapeutic opportunity for SER-155 Seres expects to submit plans for the next irEC study design to the FDA in Q1 2027 Study builds on encouraging investigator-sponsored trial (IST) results, in which 12 of 15 participants (80%) with moderate-to-severe irEC achieved an immunosuppressive-free clinical response of diarrhea following treatment with SER-155 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2026 financial results and announced it is progressing plans for a next study evaluating SER-155 for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC) in patients initiating immune checkpoint inhibitor (ICI) cancer therapy, which is expected to include a dose optimization component.
Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b clinical study of SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT) have been published in the November 3, 2026 issue of Nature Medicine.
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report)'s share price crossed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $4.48 and traded as low as $2.70. Seres Therapeutics shares last traded at $2.72, with a volume of 60,380 shares changing hands. Analyst Upgrades and Downgrades Several
Benchmark MCRB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Seres Therapeutics, Inc. (MCRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.98 | $19.17M | -0.42 | — | -2209.55% | -148.34% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — | |
| $93.72 | $5.72B | -6.85 | 54.74% | -134.75% | -734% | — | |
| $58.16 | $8.19B | -26.06 | 23258.15% | -47.79% | -60.05% | — | |
| $2.38 | $259.88M | -15.80 | — | — | -5.76% | — | |
| $0.27 | $3.31M | -0.36 | -30.91% | -694.19% | -84.43% | — |
Seres Therapeutics, Inc. (MCRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Seres Therapeutics, Inc. (MCRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 26, 2026·SEC
Aug 5, 2026·SEC
Get notified when MCRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Seres Therapeutics, Inc. (MCRB) stock FAQ — growth, dividends, profitability & financials explained
Seres Therapeutics, Inc. (MCRB) reported $2.1M in revenue over the trailing twelve months. Revenue was $0.8M in fiscal year 2025.
Seres Therapeutics, Inc. (MCRB) grew revenue by 505.4% over the trailing twelve months, compared with the twelve months before.
No. Seres Therapeutics, Inc. (MCRB) reported a net loss of $47.0M over the trailing twelve months.
Seres Therapeutics, Inc. (MCRB) had a return on equity (ROE) of -148.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Seres Therapeutics, Inc. (MCRB) had negative free cash flow of $64.0M over the trailing twelve months.
